Short Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Declines By 99.1%
by Teresa Graham · The Cerbat GemBioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 100 shares, a drop of 99.1% from the September 30th total of 11,600 shares. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is currently 0.0 days.
Bioxytran Stock Performance
BIXT opened at $0.09 on Friday. The business’s 50-day simple moving average is $0.10 and its 200-day simple moving average is $0.11. Bioxytran has a one year low of $0.07 and a one year high of $0.18. The stock has a market capitalization of $16.34 million, a P/E ratio of -3.07 and a beta of -0.89.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Featured Stories
- Five stocks we like better than Bioxytran
- Dividend Capture Strategy: What You Need to Know
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Investing In Preferred Stock vs. Common Stock
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Differences Between Momentum Investing and Long Term Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?